Intensive insulin therapy

Roche collaborates with Lilly to support people with diabetes on insulin pen therapy

Retrieved on: 
Thursday, May 6, 2021
Clinical medicine, Medicine, Organ systems, Diabetes, Insulin, Carbohydrate counting, Blood glucose monitoring, Type 1 diabetes, Injector pen, Intensive insulin therapy, Insulin pump

This integration will follow the recent launch of the Novo Nordisk smart insulin pen data integration into the mySugr app.\n"Having diabetes is often described as a full-time job.

Key Points: 
  • This integration will follow the recent launch of the Novo Nordisk smart insulin pen data integration into the mySugr app.\n"Having diabetes is often described as a full-time job.
  • The time spent on activities that come with insulin therapy blood glucose monitoring, carbohydrate counting, injections, and lifestyle planning can add up to several hours a week," said Marcel Gmuender, Global Head of Roche Diabetes Care.
  • The Tempo Smart Button will attach to Lilly\'s Tempo Pen, a modified version of Lilly\'s existing prefilled, disposable insulin pen.
  • "We are thrilled to work with Roche and mySugr to advance our goal to better support the diabetes community.

Glooko Announces Digital Health Collaboration with Eli Lilly's Connected Insulin Pen Solutions in Global Markets

Retrieved on: 
Thursday, May 6, 2021
Clinical medicine, Branches of biology, Medicine, Diabetes, Peptide hormones, Recombinant proteins, Insulin, Diabetes management, Glooko, Injector pen, Diabetes management software, Intensive insulin therapy

The integrated and actionable insights available in Glooko will improve the standard of diabetes care.\n"Lilly is a valued partner for Glooko, and we are pleased to collaborate with them on this important digital health launch," said Russ Johannesson, CEO of Glooko.

Key Points: 
  • The integrated and actionable insights available in Glooko will improve the standard of diabetes care.\n"Lilly is a valued partner for Glooko, and we are pleased to collaborate with them on this important digital health launch," said Russ Johannesson, CEO of Glooko.
  • "Studies have shown that when smart insulin devices are synced with digital health tools, it improves outcomes for people living with diabetes.
  • "Insulin dose logging is often an incomplete piece of the diabetes management puzzle for people who use insulin pens and manually track their doses.
  • By integrating data from the connected insulin pen solutions into globally-used compatible software, we aim to support improved decision-making for people with diabetes and their healthcare providers with accurate, real-time data collection.

Rapid Acting Insulin Market to Garner $8.92 Bn, Globally, by 2027 at 4.1% CAGR: Allied Market Research

Retrieved on: 
Thursday, April 22, 2021
Clinical medicine, Branches of biology, Medicine, Peptide hormones, Recombinant proteins, Diabetes, Insulin, Type 1 diabetes, Blood glucose monitoring, Insulin analog, Intensive insulin therapy

b'PORTLAND, Ore., April 22, 2021 /PRNewswire/ -- Allied Market Research recently published a report, titled, " Rapid Acting Insulin Market by Product Type (Insulin Lispro, Insulin Aspart, and Insulin Glulisine), Indication (Type 1 Diabetes and Type 2 Diabetes), and Distribution Channel (Hospital Pharmacies, Drug Stores & Retail Pharmacies, and Online Providers): Global Opportunity Analysis and Industry Forecast, 20202027".

Key Points: 
  • b'PORTLAND, Ore., April 22, 2021 /PRNewswire/ -- Allied Market Research recently published a report, titled, " Rapid Acting Insulin Market by Product Type (Insulin Lispro, Insulin Aspart, and Insulin Glulisine), Indication (Type 1 Diabetes and Type 2 Diabetes), and Distribution Channel (Hospital Pharmacies, Drug Stores & Retail Pharmacies, and Online Providers): Global Opportunity Analysis and Industry Forecast, 20202027".
  • As per the report, the global rapid acting insulin industry was accounted for $7.10 billion in 2019, and is estimated to reach $8.92 billion by 2027, growing at a CAGR of 4.1% from 2020 to 2027.\nRise in availability of continuous glucose monitoring, surge in investments in R&D for human recombinant insulin, and increase in government expenditure on healthcare drive the growth of the global rapid acting insulin market.
  • However, adverse effects associated with use of rapid acting insulin hinder the market growth.
  • However, the global rapid acting insulin market across Asia-Pacific is estimated to register the highest CAGR of 5.8% during the forecast period, owing to westernized lifestyle behaviors and the increased prevalence of obesity.\n'

Rapid Acting Insulin Market to Garner $8.92 Bn, Globally, by 2027 at 4.1% CAGR: Allied Market Research

Retrieved on: 
Thursday, April 22, 2021
Clinical medicine, Branches of biology, Medicine, Diabetes, Peptide hormones, Recombinant proteins, Insulin, Type 1 diabetes, Blood glucose monitoring, Insulin analog, Intensive insulin therapy

b'Rise in availability of continuous glucose monitoringand surge in investments in R&D for human recombinant insulin drive the growth of the global rapid acting insulin market.\nPORTLAND, Ore., April 22, 2021 /PRNewswire/ -- Allied Market Research recently published a report, titled, " Rapid Acting Insulin Market by Product Type (Insulin Lispro, Insulin Aspart, and Insulin Glulisine), Indication (Type 1 Diabetes and Type 2 Diabetes), and Distribution Channel (Hospital Pharmacies, Drug Stores & Retail Pharmacies, and Online Providers): Global Opportunity Analysis and Industry Forecast, 20202027".

Key Points: 
  • b'Rise in availability of continuous glucose monitoringand surge in investments in R&D for human recombinant insulin drive the growth of the global rapid acting insulin market.\nPORTLAND, Ore., April 22, 2021 /PRNewswire/ -- Allied Market Research recently published a report, titled, " Rapid Acting Insulin Market by Product Type (Insulin Lispro, Insulin Aspart, and Insulin Glulisine), Indication (Type 1 Diabetes and Type 2 Diabetes), and Distribution Channel (Hospital Pharmacies, Drug Stores & Retail Pharmacies, and Online Providers): Global Opportunity Analysis and Industry Forecast, 20202027".
  • As per the report, the global rapid acting insulin industry was accounted for $7.10 billion in 2019, and is estimated to reach $8.92 billion by 2027, growing at a CAGR of 4.1% from 2020 to 2027.\nRise in availability of continuous glucose monitoring, surge in investments in R&D for human recombinant insulin, and increase in government expenditure on healthcare drive the growth of the global rapid acting insulin market.
  • However, adverse effects associated with use of rapid acting insulin hinder the market growth.
  • However, the global rapid acting insulin market across Asia-Pacific is estimated to register the highest CAGR of 5.8% during the forecast period, owing to westernized lifestyle behaviors and the increased prevalence of obesity.\n'

CeQur Raises $115 Million Series C5 Financing to Support Commercialization and Scale-Up of Automated Manufacturing for CeQur Simplicity Wearable Insulin-Delivery Device

Retrieved on: 
Tuesday, April 13, 2021
Diabetes, Health, Medical devices, Clinical medicine, Branches of biology, Medicine, Diabetes, Peptide hormones, Recombinant proteins, Insulin, Bolus, Basal, Intensive insulin therapy

One Simplicity patch holds up to 200 units of rapid-acting insulin administered in two-unit increments and replaces, on average, nine mealtime injections over three days.

Key Points: 
  • One Simplicity patch holds up to 200 units of rapid-acting insulin administered in two-unit increments and replaces, on average, nine mealtime injections over three days.
  • Clinical research has shown that nearly 90% of patients using CeQur Simplicity reported following their insulin regimen better as compared to MDI.
  • 2012;29(5):682-689.\niii Based on global incidence and prevalence of patients on basal-bolus therapy and CeQur management estimates.\niv Johnson ML, Dreon DM, Levy BL, et al.
  • Paper presented at: 54th Annual Meeting of the European Association for the Study of Diabetes; October 1-5, 2018; Berlin, Germany.\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210413005506/en/\n'

BIOCORP and ROCHE DIABETES CARE FRANCE Launch Mallya, an Innovative Medical Device to Better the Daily Life of Patients With Diabetes

Retrieved on: 
Tuesday, April 13, 2021
Research, Medical devices, FDA, Diabetes, Clinical trials, Other Health, Biotechnology, Pharmaceutical, Health, Science, Clinical medicine, Medicine, Endocrine system, Peptide hormones, Recombinant proteins, Diabetes, Insulin, Injector pen, Intensive insulin therapy, Diabetes management

Developed by BIOCORP, this smart insulin pen device collects and transfers insulin data with near 100% accuracy2.

Key Points: 
  • Developed by BIOCORP, this smart insulin pen device collects and transfers insulin data with near 100% accuracy2.
  • We are really proud to be leading it with Roche Diabetes Care France.
  • We are committed to the autonomy and quality of life of patients with diabetes, empowering them to understand and act on their condition.
  • This smart sensor for insulin injection pens allows reliable monitoring of injected doses and thus offers better compliance in the treatment of patients with diabetes.

Global Insulin Pen Market Report 2020-2025: Market is Expected to Surpass US$ 35 Billion

Retrieved on: 
Wednesday, February 10, 2021
Clinical medicine, Branches of biology, Medicine, Peptide hormones, Recombinant proteins, Insulin, Injector pen, Insulin pump, Intensive insulin therapy

Global Insulin Pen Market is expected to surpass US$ 35 Billion by the end of the year 2025.

Key Points: 
  • Global Insulin Pen Market is expected to surpass US$ 35 Billion by the end of the year 2025.
  • The disposable insulin pen is also called prefilled insulin pen.
  • Smart insulin pen is the Bluetooth enabled insulin pen that records the time/date of insulin injections that have been delivered.
  • The recent addition to the pack Smart insulin pen is also known as a "connected" insulin pen.

Arecor Limited: First Patient Dosed in Phase I Clinical Trial of Ultra-Concentrated Rapid Acting Insulin Candidate, AT278, for Diabetes

Retrieved on: 
Tuesday, December 15, 2020
Clinical medicine, Branches of biology, Medicine, Peptide hormones, Recombinant proteins, Diabetes, Insulin, Insulin degludec, Intensive insulin therapy

CAMBRIDGE, United Kingdom, Dec. 15, 2020 (GLOBE NEWSWIRE) -- Arecor Limited("Arecor" or "the Company"),the biopharmaceutical company advancing today's therapies to enable healthier lives announces dosing of the first patient in a Phase I clinical trial for its second clinical stage product, an ultra-concentrated rapid acting insulin, AT278.

Key Points: 
  • CAMBRIDGE, United Kingdom, Dec. 15, 2020 (GLOBE NEWSWIRE) -- Arecor Limited("Arecor" or "the Company"),the biopharmaceutical company advancing today's therapies to enable healthier lives announces dosing of the first patient in a Phase I clinical trial for its second clinical stage product, an ultra-concentrated rapid acting insulin, AT278.
  • Sarah Howell, Chief Executive Officer at Arecor, said: "The initiation of the Phase I clinical trial for AT278, is key to the advancement of our diabetes franchise of superior fast acting insulins, focused on more personalised treatment regimens and sophisticated drug/device combinations.
  • AT278 presents a significant step towards helping people with diabetes to maintain glucose control safely and conveniently.
  • A concentrated rapid acting insulin is preferred for these patient groups.

United States Diabetes Industry Worth $26.28 Billion by 2025 - Industry and Key Players Analysis Including Braun, Eli Lilly, Artsana, BD, and Novo Nordisk Among Others

Retrieved on: 
Tuesday, August 4, 2020
Diabetes, Endocrine system, Organ systems, Clinical medicine, RTT, Diabetes management, Insulin, Type 1 diabetes, Blood glucose monitoring, Type 2 diabetes, Hypoglycemia, Intensive insulin therapy

Between the year 2000 and 2019, the number of people living with diabetes tripled and the number of new cases annually (incidence) doubled in the United States.

Key Points: 
  • Between the year 2000 and 2019, the number of people living with diabetes tripled and the number of new cases annually (incidence) doubled in the United States.
  • The United States represents the third-largest diabetes patient pool owing to the increasing geriatric population and rising obesity levels in 2018.
  • The use of continuous glucose monitoring systems and continuous subcutaneous insulin infusion has gained full acceptance in diabetes care.
  • These devices have demonstrated to be clinically valuable, reducing risks of hypoglycemia and improving glycemic control in ambulatory patients with type 1 diabetes & type 2 diabetes.

U.S. Diabetes Market Assessment 2020-2025: CGM, SMBG, Insulin Pen, Insulin Pump - ResearchAndMarkets.com

Retrieved on: 
Friday, July 31, 2020
Health, Diabetes, Clinical medicine, Endocrine system, Medicine, RTT, Diabetes management, Insulin, Blood glucose monitoring, Type 1 diabetes, Hypoglycemia, Diabetes, Intensive insulin therapy, Minimed Paradigm

The United States represents the third-largest diabetes patient pool owing to the increasing geriatric population and rising obesity levels in 2018.

Key Points: 
  • The United States represents the third-largest diabetes patient pool owing to the increasing geriatric population and rising obesity levels in 2018.
  • The use of continuous glucose monitoring systems and continuous subcutaneous insulin infusion has gained full acceptance in diabetes care.
  • These devices have demonstrated to be clinically valuable, reducing risks of hypoglycemia and improving glycemic control in ambulatory patients with type 1 diabetes & type 2 diabetes.
  • The market of Insulin Pen, Insulin Pump, Continuous Glucose Monitoring (CGM) Device and Self Monitoring Blood Glucose Device are growing due to the rise in numbers of diabetic patients in the United States.